Peptide Regulation Showdown

FDA PCAC vote recommends several peptides for 503A bulks; rulemaking 12-24 months. Industry consolidation, lawsuits, and clinical pushback continue. New physician reality check reinforces evidence gap. Recent deep-dive on MOTS-c adds to peptide knowledge. A new mainstream article features Pinchas Cohen's alarm about gray market use, reinforcing regulatory tension.